advertisement

---

1 General aspects (0)   1.1 Epidemiology (20)   1.2 Population genetics (3)   1.3 Pathogenesis (0)   1.4 Quality of life (7)   1.5 Glaucomas as cause of blindness (8)   1.6 Prevention and screening (8) 2 Anatomical structures in glaucoma (0)   2.1 Conjunctiva (8)   2.2 Cornea (27)   2.3 Sclera (2)   2.4 Anterior chamber angle (2)   2.5 Meshwork (0)     2.5.1 Trabecular meshwork (8)     2.5.2 Schlemms canal (3)     2.5.3 Scleral outlet channels (0)   2.6 Aqueous humor dynamics (0)     2.6.1 Production (2)     2.6.2 Outflow (1)       2.6.2.1 Trabecular meshwork (5)       2.6.2.2 Uveoscleral (0)     2.6.3 Compostion (8)   2.7 Episcleral veins and venous pressure (0)   2.8 Iris (4)   2.9 Ciliary body (1)   2.10 Lens (1)   2.11 Vitreous body (1)   2.12 Choroid, peripapillary choroid, peripapillary atrophy (3)   2.13 Retina and retinal nerve fibre layer (22)   2.14 Optic disc (22)   2.15 Optic nerve (1)   2.16 Chiasma and retrochiasmal central nervous system (4)   2.17 Stem cells (2)   2.20 Other (0) 3 Laboratory methods (0)   3.1 Microscopy (2)   3.2 Electron microscopy (2)   3.3 Immunohistochemistry (5)   3.4 Molecular genetics (0)     3.4.1 Linkage studies (1)     3.4.2 Gene studies (36)   3.5 Molecular biology incl. SiRNA (11)   3.6 Cellular biology (34)   3.7 Biochemistry (10)   3.8 Pharmacology (19)   3.9 Pathophysiology (7)   3.10 Immunobiology (11)   3.11 Pharmacogenetics (0)   3.12 Proteomics (2)   3.13 In vivo imaging (0)     3.13.1 Laser Scanning (0)       3.13.1.1 Confocal Scanning Laser Ophthalmoscopy (0)       3.13.1.2 Confocal Scanning Laser Polarimetry (0)     3.13.2 Optical Coherence Tomography (0)       3.13.2.1 Anterior Segment (0)       3.13.2.2 Posterior Segment (0)     3.13.3 RGC Imaging (3)     3.13.4 Other (0)   3.20 Other (0) 4 Tissue culture of ocular cells (0) 5 Experimental glaucoma; animal models (0)   5.1 Rodent (46)   5.2 Primates (3)   5.3 Other (22) 6 Clinical examination methods (0)   6.1 Intraocular pressure measurement; factors affecting IOP (0)     6.1.1 Devices, techniques (15)     6.1.2 Fluctuation, circadian rhythms (7)     6.1.3 Factors affecting IOP (26)   6.2 Tonography, aqueous flow measurement (see also 2.6) (3)   6.3 Biomicroscopy (slitlamp) (0)     6.3.1 Anterior segment (1)     6.3.2 Posterior segment (1)   6.4 Gonioscopy (0)   6.5 Ophthalmoscopy (2)   6.6 Visual field examination and other visual function tests (0)     6.6.1 Conventional manual (0)     6.6.2 Automated (21)     6.6.3 Special methods (e.g. color, contrast, SWAP etc.) (14)   6.7 Electro-ophthalmodiagnosis (8)   6.8 Photography (0)     6.8.1 Anterior segment (3)     6.8.2 Posterior segment (11)   6.9 Computerized image analysis (0)     6.9.1 Laser scanning (0)       6.9.1.1 Confocal Scanning Laser Ophthalmoscopy (16)       6.9.1.2 Confocal Scanning Laser Polarimetry (8)     6.9.2 Optical coherence tomography (0)       6.9.2.1 Anterior (10)       6.9.2.2 Posterior (46)     6.9.5 Other (0)   6.10 Fluorescein (ICG) angiography (0)     6.10.1 Anterior segment (0)     6.10.2 Posterior segment (3)   6.11 Bloodflow measurements (26)   6.12 Ultrasonography and ultrasound biomicroscopy (6)   6.13 Provocative tests (1)   6.19 Telemedicine (1)   6.20 Progression (7)   6.30 Other (0) 8 Refractive errors in relation to glaucoma (0)   8.1 Myopia (4)   8.2 Hypermetropia (0)   8.3 Contact lenses (0)   8.4 Refractive surgical procedures (0)   8.5 Other (0) 9 Clinical forms of glaucomas (0)   9.1 Developmental glaucomas (0)     9.1.1 Congenital glaucoma, Buphthalmos (7)     9.1.2 Juvenile glaucoma (13)     9.1.3 Syndromes of Axenfeld, Rieger, Peters, aniridia (4)     9.1.4 Other (0)   9.2 Primary open angle glaucomas (0)     9.2.1 Ocular hypertension (3)     9.2.2 Other risk factors for glaucoma (4)     9.2.3 Open angle glaucoma with elevated IOP (4)     9.2.4 Normal pressure glaucoma (15)   9.3 Primary angle closure glaucomas (0)     9.3.1 Acute primary angle closure glaucoma (pupillary block) (13)     9.3.2 Chronic primary angle closure glaucoma (pupillary block) (5)     9.3.3 Plateau iris syndrome (0)     9.3.4 Primary angle closure suspect (2)     9.3.5 Primary angle closure (6)     9.3.10 Other (0)   9.4 Glaucomas associated with other ocular and systemic disorders (0)     9.4.1 Steroid-induced glaucoma (5)     9.4.2 Glaucomas associated with disorders of the cornea, conjunctiva, sclera (0)       9.4.2.1 Iridocorneal endothelial syndrome (ICE, incl. irisatrophy) (0)       9.4.2.2 Posterior polymorphous dystrophy (0)       9.4.2.3 Fuchs' endothelial dystrophy (0)       9.4.2.5 Other (0)     9.4.3 Glaucomas associated with disorders of the iris and ciliary body (0)       9.4.3.1 Pigmentary glaucoma (2)       9.4.3.5 Other (0)     9.4.4 Glaucomas associated with disorders of the lens (0)       9.4.4.1 Exfoliation syndrome (14)       9.4.4.2 Glaucomas associated with cataracts (4)       9.4.4.3 Glaucomas associated with lens dislocation (0)       9.4.4.5 Other (4)     9.4.5 Glaucomas associated with disorders of the retina, choroid and vitreous (0)       9.4.5.1 Neovascular glaucoma (7)       9.4.5.5 Other (1)     9.4.6 Glaucomas associated with inflammation, uveitis (6)     9.4.7 Glaucomas associated with ocular trauma (0)     9.4.8 Glaucomas associated with intraocular tumors (1)     9.4.9 Glaucomas associated with elevated episcleral venous pressure (1)       9.4.10 Glaucomas associated with hemorrhage (2)     9.4.11 Glaucomas following intraocular surgery (0)       9.4.11.1 Ciliary block (malignant) glaucoma (4)       9.4.11.2 Glaucomas in aphakia and pseudophakia (6)       9.4.11.3 Epithelial, fibrous, and endothelial proliferation (0)       9.4.11.4 Glaucomas associated with corneal surgery (6)       9.4.11.5 Glaucomas associated with vitreoretinal surgery (4)     9.4.15 Glaucoma in relation to systemic disease (24)     9.4.20 Other (1) 10 Differential diagnosis e.g. anterior and posterior ischemic optic neuropathy (6) 11 Medical treatment (0)   11.1 General management, indication (2)   11.2 Cholinergic drugs (0)   11.3 Adrenergic drugs (0)     11.3.1 Epinephrine (0)     11.3.2 Thymoxamine, dapiprazole (0)     11.3.3 Apraclonidine, brimonidine (4)     11.3.4 Betablocker (7)     11.3.5 Other (0)   11.4 Prostaglandins (19)   11.5 Carbonic anhydrase inhibitors (0)     11.5.1 Systemic (1)     11.5.2 Topical (7)   11.6 Osmotic treatment (0)   11.7 Treatment of bloodflow (1)   11.8 Neuroprotection (43)   11.9 Gene therapy (1)   11.13 Combination therapy (0)     11.13.1 Betablocker and pilocarpine (0)     11.13.2 Betablocker and carbon anhydrase inhibitor (6)     11.13.3 Betablocker and brimonidine (1)     11.13.4 Betablocker and prostaglandin (6)     11.13.5 Other (0)   11.14 Investigational drugs; pharmacological experiments (20)   11.15 Other drugs in relation to glaucoma (13)   11.16 Vehicles, delivery systems, pharmacokinetics, formulation (23)   11.17 Cooperation with medical therapy e.g. persistency, compliance, adherence (8)   11.20 Other (3) 12 Surgical treatment (0)   12.1 General management, indication (2)   12.2 Laser iridotomy (3)   12.3 Laser iridoplasty (0)   12.4 Laser trabeculoplasty and other laser treatment of the angle (8)   12.7 Surgical iridectomy (1)   12.8 Filtering surgery (0)     12.8.1 Without tube implant (20)     12.8.2 With tube implant or other drainage devices (26)     12.8.3 Non-perforating (10)     12.8.4 Using laser (0)     12.8.5 Other (0)     12.8.10 Woundhealing antifibrosis (26)     12.8.11 Complications, endophthalmitis (5)   12.9 Trabeculotomy, goniotomy (0)   12.10 Cyclodestruction (7)   12.11 Cyclodialysis (0)   12.12 Cataract extraction (0)     12.12.1 Intracapsular (0)     12.12.2 Extracapsular (1)     12.12.3 Phacoemulsification (7)   12.14 Combined cataract extraction and glaucoma surgery (0)     12.14.1 Intracapsular (0)     12.14.2 Extracapsular (1)     12.14.3 Phacoemulsification (5)   12.15 Capsulotomy (0)   12.16 Vitrectomy (1)   12.17 Anesthesia (4)   12.20 Other (3) 13 Therapeutic prognosis and outcome (0)   13.1 Prognostic factors (0)   13.2 Outcome (0)     13.2.1 IOP (0)     13.2.2 Visual field (0)       13.2.2.1 Progression (2)       13.2.2.2 Improvement (1)     13.2.3 Other (0) 14 Costing studies; pharmacoeconomics (6) 15 Miscellaneous (25)

---

Abstract #26959 Published in IGR 12-4

Quantification of the effect of different levels of IOP in the astroglia of the rat retina ipsilateral and contralateral to experimental glaucoma.

Ramírez AI; Salazar JJ; de Hoz R; Rojas B; Gallego BI; Salinas-Navarro M; Alarcón-Martínez L; Ortín-Martínez A; Avilés-Trigueros M; Vidal-Sanz M
Investigative Ophthalmology and Visual Science 2010; 51: 5690-5696

---

PURPOSE: To analyze the effects of different levels of intraocular pressure (IOP) in the macroglia in ocular hypertension (OHT) and contralateral eyes at 3 weeks after laser photocoagulation and compare these with effects in age-matched control rats. METHODS: Adult Sprague-Dawley rats were divided into an age-matched control (naive) group and an OHT group. Retinas were processed as whole mounts and immunostained with GFAP for analysis of the retinal macroglia. RESULTS: The area of the retina occupied by astrocytes (AROA) was quantified. GFAP immunostaining showed common features in ipsilateral and contralateral eyes. First, although the astrocyte network maintained a star-shaped morphology, these cells had fewer secondary processes and thinner cell bodies and primary processes than did naive cells. Second, Müller cells appeared as punctate GFAP+ structures among astrocytes. Third, there was a significant reduction of the AROA in ipsilateral and contralateral eyes compared with naive eyes. Ipsilateral eyes had significantly less AROA than did contralateral eyes. The decrease was greater for OHT eyes with higher IOP levels. CONCLUSIONS: OHT induces changes in the macroglia of contralateral eyes; thus, these fellow eyes should not be used as control. In eyes with OHT, there is a close relationship between IOP values and decreased AROA.

Instituto de Investigaciones Oftalmológicas Ramón Castroviejo, Universidad Complutense, Madrid, Spain. ramirezs@med.ucm.es

---

Classification:

5.1 Rodent (Part of: 5 Experimental glaucoma; animal models)
11.8 Neuroprotection (Part of: 11 Medical treatment)

---

• ← Previous
• Next →

---